FDA Brief

Warning letters Biologics

FDA warning letter to

The New Hope Center for Reproductive Medicine

High riskIssued Jun 27, 2023Posted Jul 11, 2023Division of Biological Products Operations I

FDA warns Virginia Beach fertility center over incomplete donor screening and testing for reproductive tissue.

What happened

FDA inspected The New Hope Center for Reproductive Medicine in Virginia Beach, VA, from December 8, 2022 to January 23, 2023. It found donor records missing required screening questionnaires or current physical exams, and donor specimens collected outside required timeframes. FDA also found donor eligibility procedures deficient and called the firm’s corrective response inadequate.

What FDA found

  1. Failed to screen donors by reviewing current medical records, including a donor history questionnaire and physical exam, for communicable disease risk factors.

    21 CFR 1271.75(a)
  2. Failed to collect donor specimens for communicable disease testing within the required timeframes around recovery.

    21 CFR 1271.80(b)
  3. Failed to establish and maintain complete procedures for donor testing, screening, and eligibility determination.

    21 CFR 1271.47(a)
  4. Because screening and testing were incomplete, donor eligibility determinations were incomplete and affected products had to remain in quarantine.

    21 CFR 1271.50(a); 21 CFR 1271.60(a)

What FDA wants

FDA asks the firm to respond in writing within 15 working days with specific corrective steps and supporting documentation. FDA also says affected oocytes, semen, and embryos must stay in quarantine unless an exemption is granted or required labeling is used.

Who should pay attention

  • fertility clinics using donor oocytes or semen
  • sperm and egg banks
  • patients receiving donor reproductive tissue

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  2. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  3. Louisville Reproductive Center

    Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

    High risk
  4. Green Valley Fertility Partners

    FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

    High risk